已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial

恩帕吉菲 格列美脲 医学 二甲双胍 2型糖尿病 临床终点 内科学 磺酰脲 糖尿病 随机对照试验 内分泌学 胰岛素
作者
Martin Ridderstråle,Knut Robert Andersen,Cordula Zeller,Gabriel Kim,Hans J. Woerle,Uli C. Broedl
出处
期刊:The Lancet Diabetes & Endocrinology [Elsevier]
卷期号:2 (9): 691-700 被引量:325
标识
DOI:10.1016/s2213-8587(14)70120-2
摘要

Summary

Background

Metformin is the recommended first-line pharmacotherapy for patients with type 2 diabetes. There is no consensus on the optimum second-line pharmacotherapy. We compared the efficacy and safety of the sodium glucose cotransporter 2 inhibitor empagliflozin and the sulfonylurea glimepiride as add-on to metformin in patients with type 2 diabetes.

Methods

In this double-blind phase 3 trial, patients (aged ≥18 years) with type 2 diabetes and HbA1c concentrations of 7–10%, despite metformin treatment and diet and exercise counselling, were randomly assigned in a 1:1 ratio with a computer-generated random sequence, stratified by HbA1c, estimated glomerular filtration rate (eGFR), and region, to empagliflozin (25 mg once daily, orally) or glimepiride (1–4 mg once daily, orally) as add-on to metformin for 104 weeks. Patients and investigators were masked to treatment assignment. The primary endpoint was change from baseline in HbA1c levels at weeks 52 and 104. Differences in the primary endpoint were first tested for non-inferiority (based on a margin of 0·3%). If non-inferiority was shown, differences in the primary endpoint at week 104 were then tested for superiority. Analysis was done on the full-analysis set—ie, patients who were treated with at least one dose of study drug and had a baseline HbA1c value. This study is registered with ClinicalTrials.gov, number NCT01167881. A 104-week extension is ongoing.

Findings

Between August, 2010, and June, 2011, 1549 patients were randomly assigned to receive empagliflozin (n=769) or glimepiride (n=780); four patients in the empagliflozin group did not receive the assigned treatment. Empagliflozin was non-inferior to glimepiride at both timepoints. At week 104, adjusted mean difference in change from baseline in HbA1c with empagliflozin versus glimepiride was −0·11% (95% CI −0·19 to −0·02; p=0·0153 for superiority). Adverse events were reported in 661 (86%) patients treated with empagliflozin and 673 (86%) patients treated with glimepiride. Severe adverse events were reported in 72 (9%) patients in the empagliflozin group and 68 (9%) in the glimepiride group. Serious adverse events were reported in 119 (16%) patients in the empagliflozin group and 89 (11%) in the glimepiride group. Confirmed hypoglycaemic adverse events (plasma glucose ≤3·9 mmol/L or requiring assistance) at week 104 were reported in 19 (2%) patients treated with empagliflozin and 189 (24%) patients treated with glimepiride.

Interpretation

Empagliflozin might be an effective and a well tolerated second-line treatment option for patients with type 2 diabetes who have not achieved good glycaemic control on metformin.

Funding

Boehringer Ingelheim and Eli Lilly.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
土豪的泥猴桃完成签到,获得积分10
2秒前
cm完成签到,获得积分10
4秒前
义气的元柏完成签到 ,获得积分10
4秒前
蓝天完成签到,获得积分10
4秒前
和平完成签到 ,获得积分10
7秒前
Orange应助从容的凛采纳,获得10
7秒前
10秒前
11秒前
14秒前
14秒前
15秒前
额123没名完成签到 ,获得积分10
15秒前
19秒前
ming发布了新的文献求助10
19秒前
落落完成签到 ,获得积分0
22秒前
若水完成签到 ,获得积分10
22秒前
vimeid完成签到 ,获得积分10
24秒前
24秒前
AlexLam完成签到,获得积分10
25秒前
华仔应助聪慧的从云采纳,获得10
26秒前
可乐完成签到 ,获得积分10
26秒前
27秒前
28秒前
cjw完成签到,获得积分10
30秒前
可爱的函函应助atuoei采纳,获得10
31秒前
Georgechan完成签到,获得积分10
31秒前
LU完成签到 ,获得积分10
32秒前
32秒前
微笑的铸海完成签到 ,获得积分10
34秒前
34秒前
牛牛发布了新的文献求助10
34秒前
Sunshine完成签到 ,获得积分10
35秒前
35秒前
36秒前
苹果炎彬发布了新的文献求助10
36秒前
Blaseaka完成签到 ,获得积分10
36秒前
符fu完成签到 ,获得积分10
37秒前
WRX发布了新的文献求助10
37秒前
zz完成签到,获得积分10
38秒前
40秒前
高分求助中
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Le dégorgement réflexe des Acridiens 800
Defense against predation 800
Very-high-order BVD Schemes Using β-variable THINC Method 568
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3136953
求助须知:如何正确求助?哪些是违规求助? 2787893
关于积分的说明 7783824
捐赠科研通 2443962
什么是DOI,文献DOI怎么找? 1299536
科研通“疑难数据库(出版商)”最低求助积分说明 625464
版权声明 600954